Galmed制药 GLMD 深 沪
等待开盘 12-20 09:30:00 美东时间
0.8702
-0.019
-2.10%
华盛通- 最 高1.00
- 今 开0.916
- 成交量 2.55万股
- 最 低 0.8701
- 昨 收 0.8889
- 总市值 476.80万
- 52周最高 3.61
- 市盈率 静 --
- 换手率 0.46%
- 52周最低 0.7449
- 委 比 33.33%
- 总股本 547.92万
- 历史最高 4870.80
- 量 比 0.42
- 振 幅 14.61%
- 历史最低 0.7449
- 每 手 1
- 风险率 0.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Galmed Pharma Granted Patent In South Korea For Aramchol And Rezdiffra Combination Therapy In NASH/MASH And Liver Fibrosis
The new patent granted in South Korea is added to earlier patents already granted by the United States Patent and Trademark Office (USPTO), Europe, Canada and other jurisdictions and will expire in the U.S. in July
12-04 21:36
Galmed Issues CEO Letter to Shareholders
TEL AVIV, Israel, Dec. 1, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometa...
12-01 21:30
Galmed Pharmaceuticals Q3 EPS $(0.33) Beats $(0.54) Estimate
Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.54) by 38.89 percent. This is a 85.71 percent increase over losses of $(2.31) per share
11-26 21:34
Galmed Pharmaceuticals Reports Top-Line Results From AM-001 Phase 1 Bioavailability Study, Demonstrating Enhanced Pharmacokinetic Profile Of Aramchol Meglumine Granules
The top-line results showed that bioavailability of Aramchol meglumine 400mg and 200mg granules is considerably greater, higher by 5-fold and 3-fold respectively, that of the Aramchol free acid 300mg tabletsThe new
11-18 21:44
Globus Medical Schedules Third Quarter Earnings Release and Conference Call
Globus Medical plans to release its Q3 2025 financial results after the market close on November 6, 2025. A webcast and conference call will discuss the performance at 4:30 p.m. ET. Registration for the call is available via a provided link. An audio archive will be accessible post-call on their website.
10-16 20:30
Globus Medical Launches ANTHEM™ Elbow Fracture System: A Comprehensive Plating Portfolio for Complex Elbow Trauma
Globus Medical has launched the ANTHEM™ Elbow Fracture System, a comprehensive solution for treating various elbow fractures. Featuring 14 plate families, screw options, and anatomical instruments, the system simplifies surgeries and offers versatility for complex fractures. With polyaxial locking technology enabling flexible screw placement, the ANTHEM™ System enhances fixation accuracy. surgeons praise its design and flexibility, highlighting i...
10-14 20:40
Galmed Pharmaceuticals Q2 EPS $(0.63) Beats $(0.83) Estimate
Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.83) by 24.1 percent. This is a 61.82 percent increase over losses of $(1.65) per share
08-28 21:36
Globus Medical, Inc. Secures Jury Verdict in Delaware Patent Litigation Against Life Spine, Inc.
Globus Medical, a leading musculoskeletal technology company, announced that a Delaware jury ruled in its favor in a patent infringement case against Life Spine, Inc. The jury found Life Spine's Prolift implants infringed Globus' valid patent and awarded both lost profits and reasonable royalty damages. The technology in question involves expandable spinal fusion implants, which improve patient outcomes in spinal surgery. Keith Pfeil, President a...
08-28 20:30
MASH drug developers rise as FDA accepts lenient trial requirement
Drug developers with products targeting a liver condition called metabolic dysfunction-associated steatohepatitis (MASH) traded higher on Wednesday after the U.S. FDA said it has accepted an easy-to-m...
08-28 01:44
Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Shares of Palo Alto Networks, Inc. (NASDAQ:PANW) rose sharply in pre-market tra...
08-19 20:01
